2083
Most common cause of inherited mental retardation.
The leading single gene cause of autism and intellectual disability.
The most frequent form of inherited intellectual impairment, with a prevalence between one in 4000 and one in 6000 males.
The prevalence in females is approximately 1/2 of that in males.
Most male patients with fragile X syndrome, have substantial intellectual disabilities and approximately 60% have autism.
Female patients are affected to a lesser degree because the normal X chromosome allele produces fragile X ribonuclear protein-1 (FMRP).
Approximately 1/3 of female patients who have full mutation has intellectual disability and 1/3 have a borderline IQ and 1/3 have a normal normal IQ.
Learning and emotional problems are common and even with a normal IQ.
Carrier rate is approximately 1 in 750 men and one in 250 women.
Mutations in the Fragile X mental retardation 1 (FMR1) gene may cause multiple disorders that can occur through a lifespan and includes: fragile X. syndrome, and premature menopause, known as primary ovarian insufficiency, late onset neurodegenerative disorders, fragile X associated trauma/ataxia syndrome.
Premutation is more common than full mutation, occurring in one in 159 to 200 females and about one and 400 male persons in the general population.
FXTAS (Fragile-associated tremor-associated syndrome) is one of the most common single gene forms of adult onset neurodegeneration, generally manifesting with gait ataxia or intention tremor, along with features of progressive cognitive decline, neuropathy, and dysautonomia.
The fragile site appears as a break on the bottom end of the X chromosome: Xq22.3
It is caused by a change in a gene called FMR1, as a small part of the gene code is repeated on a fragile area of the X.
FMR1 gene, among other genes, can lead to disease through trinucleotide expansions.
FMR1 CGG expansions ( greater than 200 CGG repeats) may result in the absence of protein space (FMRP) which is important for synapse function.
In carriers of smaller, premutation alleles of 55-200 CGG repeats, a disease process with increased expression and RNA toxicity occurs.
The vast majority of cases leads to intellectual disability and autism caused by a CGG-repeat expansion to greater than 200 repeats in the 5’ non-coding region of FMR1.
The promoter region of full mutation alleles is usually fully methylated which silences the gene from transcription and results in the production of little and no messenger RNA and subsequently little or no FMRP, the protein encoded by FMR1 from that allele, thus fragile X syndrome is a loss of function condition.
Individuals carrying a full mutation form of the FMR1 gene may have intellectual and developmental abnormalities, which can include psychiatric and emotional diseases that may manifest even individuals with normal IQ level.
Males and females can both be affected, but because males have only one X chromosome, a single fragile X is likely to affect them more.
Most fragile-X males have large testes, big ears, narrow faces, and sensory processing disorders that result in learning disabilities.
Autism is seen in the majority of cases with fragile X. syndrome.
Shyness, social anxiety, and autistic behavior is common in girls with the full mutation of the FMR1 gene.
Majority of children with the pre-mutation have normal mental capacity, but they may have developmental problems with attention and social communication in boys (Farzin F).
Approximately 3% of boys with special needs have fragile X syndrome.
Caused by absent or decreased levels of fragile X mental retardation protein (FMRT) gene.
The FMR1 loss of function mutation gene is located on Xq27.3.
More than 99% of cases or related to the loss of function caused by an unstable expansion of a trinucleotide (CGG) repeat at the 5′ untranslated region.
Fewer than 1% of cases are related to deletions, point mutations, or missense mutations in the FMR1 The one gene.
X-linked recessive disease with variable expression and incomplete penetrance.
Mutations in a single gene fragile X mental retardation 1 (FMR1) cause a number of disorders occurring throughout the entire life span.
FMR1 mutations cause heritable form of intellectual disability, fragile X syndrome, and premature menopause.
The most frequent form of inherited intellectual impairment, with a prevalence between one in 4000 and one in 6000 males.
Mutations of FMR1 cause late onset neurodegenerative disorders, fragile X-associated tremor/ataxia syndrome (FXTAS).
FXTAS generally occurs after 50 years of age, and the mean age of onset is 62 years and among 8 to 10 to 16% of female carriers.
In addition to gateataxia and tremor, dementia develops in 50% of men with FXTAS but is seen in fewerwomen with the syndrome.
Brain atrophy and white matter changes on MRI typically are found in the middle cerebeller peduncles in 60% of men with FXTAS, in the splenium of the corpus callosum in 64% of women with the syndrome, and in the preventricular areas.
With progression of the disease, atrophy and white matter changes can extend into the frontal, parietal, and occipital areas, and ultimately the ventricles become enlarged.
Peripheral neuropathy that manifest in the legs and feet occur the most patient with FXTAS, and Parkinsonian features such as resting tremor and shuffling gait occur in approximately 30% of those affected.
Neuropathologic features of FXTAS include spongiform changes in the white matter , eosinophilic positive and tau-negative intranuclear inclusions in neurons, and astrocytes that contain proteins that undergo ubiquitination and sumoylation, and neurofilaments.
RNA and repeat associated non-AUG toxicity in permutation carries leads to mitochondrial dysfunction, and has the oxidative stress, calcium iron dysregulation, eventually leading to neuronal and astrocyte death.
30% of all carrier women are affected.
A fragile site or gap exists at the end of the long arm of the X-chromosome in the lymphocytes of affected patients when grown in a folate deficient medium.
Carrier mothers typically have a 30-40% chance of giving birth to a retarded male and a 15-20% chance of having a retarded daughter.
Frequently a maternal family history of having a mentally retarded or learning disabled relative.
Classic findings include: long face, prominent jaw, post-pubertal macroochidism, large prominent ears, high arched plate, flattened nasal bridge, micro or microcephaly, hypertelorism, epicanthal folds, simian palm creases, vertical sole creases, long philtrum, hemangioma and hyperextensible joints.
Classic physical findings appear in children as young as 2-3 years of age but usually are apparent by 8-12 years of.
Fragile X syndrome is usually diagnosed in approximately three years of age when delayed speech becomes apparent, and the child is typically hypotonic, anxious, hyperactive with tantrums.
Autism is often diagnosed before Fragile syndrome due to social deficits and anxiety.
Fragile X DNA testing is appropriate for children with autism or intellectual disability.
Patients may have connective tissue changes, including soft skin, owing to the lack of elastin infrastructure in the dermis, prominent and elongated ear pinnae, elongated face, high palate, flat feet, hyperextensible, finger joints, and pubescent, macrorchidism.
Elongated face is more common commonly noted in adults and medical problems associated with fragile X syndrome include frequent otitis media in the first 3 to 4 years of life, gastroesophageal reflux, hernia, and occasional joint dislocations.
Seizures are reported in approximately 16% of male, and in less than 5% of female patients.
Young children may present with developmental delay, speech delay, impaired attention span, discipline problems, autistic behaviors, poor motor coordination, persistence of drooling and hypotonia.
The spectrum of behavioral, cognitive and physical changes associated with the syndrome are, in part due to FMRP levels in the blood, which reflect levels in all tissues, including the brain and can vary according to the sex of the child or the degrees of methylation and mosaicism.
Fragile X associated primary ovarian insufficiency (FXPOI) manifest approximately 20% of female permutation carriers before 40 years of age, and is the most common hereditary form of ovarian failure or insufficiency.
The disorder is most likely to occur in a range of CGG repeats between 75 and 100 and though there is no specific treatment, hormone replacement therapy has been recommended.
Several cases in which the carrier have been able to conceive after diagnosis.
Fragile X – associated neuropsychiatric disorders, include depression, anxiety, insomnia, obsessive compulsive behavior, chronic fatigue, and chronic pain.
One or more of these disorders occurs in approximately 50% of female carriers who present clinically.
Medical disorders that occurred higher rate among premutation carriers, and in the general population: hypertension, migraine, headaches, and autoimmune disorders, fibromyalgia, lupus, and multiple sclerosis.
Management:
No specific treatment for fragile X syndrome is approved.
Stimulant medications may be used for ADHD symptoms, and selective serotonin reuptake inhibitors are recommended for anxiety, which is common in Fragile X syndrome.
Aggression and anxiety, particularly in males, may be managed with atypical antipsychotics such as aripiprazole.
mGluR5 antagonists, Cannabidiol (CBD) gel. phosphodiesterase-4D inhibitor zatolmilast, Metformin, GABAergic agents such as ganaxolone and allopregnanolone are under investigation.
Building on the symptomatic and investigational approaches described above, current management of Fragile X syndrome (FXS) relies on a combination of non-pharmacological interventions and targeted pharmacotherapy, tailored to individual needs.
Early developmental and educational interventions—including speech and language therapy, occupational therapy, behavioral therapy, and individualized educational support—are considered foundational and should be initiated as soon as possible to optimize outcomes.
These therapies address core deficits in communication, motor skills, and adaptive functioning.
Stimulant medications may be used for ADHD symptoms, and selective serotonin reuptake inhibitors are recommended for anxiety, which is common in Fragile X syndrome.
Aggression and anxiety, particularly in males, may be managed with atypical antipsychotics such as aripiprazole.
mGluR5 antagonists, Cannabidiol (CBD) gel. phosphodiesterase-4D inhibitor zatolmilast, Metformin, GABAergic agents such as ganaxolone and allopregnanolone are under investigation.
Building on the symptomatic and investigational approaches described above, current management of Fragile X syndrome (FXS) relies on a combination of non-pharmacological interventions and targeted pharmacotherapy, tailored to individual needs.
Early developmental and educational interventions—including speech and language therapy, occupational therapy, behavioral therapy, and individualized educational support—are considered foundational and should be initiated as soon as possible to optimize outcomes.
These therapies address core deficits in communication, motor skills, and adaptive functioning.
Pharmacologic treatment is primarily symptom-based.
SSRIs are commonly used for anxiety and mood symptoms, while stimulants may be prescribed for ADHD features.
Antipsychotics, such as aripiprazole or risperidone, are reserved for severe aggression or self-injurious behavior, but should be used cautiously due to increased sensitivity to side effects in FXS.
Minocycline, acamprosate, and lovastatin have shown benefit in open-label studies for behavioral and cognitive symptoms, though robust evidence is limited.
Gene therapy and other molecular approaches are in preclinical development and may offer disease-modifying potential in the future.
Overall, a multidisciplinary, individualized approach combining behavioral, educational, and pharmacologic strategies remains the standard of care, with ongoing research into targeted and disease-modifying therapies.
Pharmacologic treatment is primarily symptom-based.
SSRIs are commonly used for anxiety and mood symptoms, while stimulants may be prescribed for ADHD features.
Antipsychotics, such as aripiprazole or risperidone, are reserved for severe aggression or self-injurious behavior, but should be used cautiously due to increased sensitivity to side effects in FXS.
Minocycline, acamprosate, and lovastatin have shown benefit in open-label studies for behavioral and cognitive symptoms, though robust evidence is limited.
Gene therapy and other molecular approaches are in preclinical development and may offer disease-modifying potential in the future.
Overall, a multidisciplinary, individualized approach combining behavioral, educational, and pharmacologic strategies remains the standard of care, with ongoing research into targeted and disease-modifying therapies.
The phosphodiesterase-4D inhibitor zatolmilast (BPN14770) is an investigational agent that has shown improvement in language and daily functioning in a small adult study and is currently in phase 3 trials.
Metformin, which modulates the mTOR pathway, has shown stabilization of IQ and adaptive behavior in limited open-label studies, but controlled trial results are pending.
Current consensus emphasizes a multimodal strategy combining behavioral, educational, and pharmacologic interventions tailored to individual needs.
Early developmental and educational evaluation is critical, with integration of speech, occupational, and physical therapies within specialized educational programs shown to improve outcomes for children with fragile X syndrome (FXS).
Individualized educational support, small class sizes, and avoidance of sudden changes are recommended to address learning difficulties and behavioral challenges.
Pharmacologic management is symptom-driven.
SSRIs (e.g., sertraline) are commonly used for anxiety and mood symptoms, while stimulants may be considered for comorbid ADHD.
Minocycline, acamprosate, lovastatin, and sertraline have demonstrated benefit in open-label and controlled trials for behavioral and cognitive symptoms in FXS.
Importantly, individuals with FXS are more sensitive to psychotropic adverse effects, so medications should be initiated at low doses and titrated cautiously.
Metformin has shown promise in preclinical and early clinical studies for improving behavioral and cognitive outcomes, particularly when initiated early in life.
Modulation of the mGluR5 pathway remains a focus, with mGluR5 antagonists and other agents targeting glutamatergic and GABAergic signaling in ongoing trials.
Gene therapy and molecular approaches, such as antisense oligonucleotides to restore FMRP expression, have potential for disease modification.
Routine medical management of associated conditions, seizures, otitis media, cardiac issues follows standard practice, and supportive care is essential.
Stimulant medications may be used to treat patients with ADHD and selective serotonin reuptake inhibitor can be used in the treatment of anxiety, which is present and almost all persons with fragile X syndrome.
Anxiety can lead to aggression in 30 to 40% of male and approximate 20% a female patients with fragile X syndrome.